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Brugada syndrome (BrS) is characterized by ST-segment
elevation in right precordial leads on 12-lead electrocardio-
gram (ECG) with associated sudden cardiac death because of
ventricular ﬁbrillation (VF).1 The ECGmanifestations of this
syndrome are often dynamic or concealed and may be
unmasked or modulated by sodium channel blockers, febrile
state, vagotonic agents, α-adrenergic agonists, β-adrenergic
blockers, a combination of glucose and insulin, hypo- and
hyperkalemia, alcohol or cocaine toxicity, and tricyclic
antidepressants, as well as other medical drugs.2 In sympto-
matic patients the implantation of an implantable
cardioverter-deﬁbrillator (ICD) is recommended, with or
without medical treatment, with the purpose of reduction
of the ionic imbalance at the end of phase 1 of action
potential, inhibitors of potassium outward currents (ito), or
drugs that increase calcium currents (ICaL).3 In 2011
Nademanee et al4 published a case series of 9 symptomatic
patients with BrS who had recurrent VF episodes and ICD
discharges who underwent epicardial ablation of the right
ventricular outﬂow tract (RVOT). As Sacher et al5 discov-
ered later and then published by Boyle and Shivkumar6, in
this location low voltages with prolonged duration and
fractionated late potentials were found, and preliminary
studies have shown an absence of clinical recurrence after
the procedure of 78% in a 20-month follow-up.7–9KEYWORDS Brugada syndrome; Cardiac mapping; Flecainide; Epicardium;
Ablation
ABBREVIATIONS BrS ¼ Brugada syndrome; ECG ¼ electrocardiogram;
ICD ¼ implantable cardioverter-defibrillator; RF ¼ radiofrequency;
RV ¼ right ventricle; RVOT ¼ right ventricular outflow tract; VF ¼
ventricular fibrillation; VT ¼ ventricular tachycardia
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We present the case of a 33-year-old man, who in 2010
presented with recovered sudden cardiac death associated
with VF and debut of BrS with type 1 transitory pattern. A
VVI/ICD was implanted as secondary prevention and
genetic testing for BrS susceptibility genes was performed,
with negative results. The patient remained asymptomatic
until 2013, when he presented with a VF episode with ICD
appropriate discharge. In December 2014, 2 VF episodes
were treated, also with ICD appropriate discharges. Medical
treatment was initiated with quinidine sulfate 400 mg/8 hours
but it was suspended 1 month later because of severe
diarrhea, asthenia, and 7 kg weight loss. Two months later,
the patient presented 2 VF episodes with ICD appropriate
discharges, so epicardial ablation was proposed. Dynamic
ECG manifestations of Brugada syndrome were clearly
observed in this patient (Figure 1A–E). At the beginning of
electrophysiological study, BrS type 2 pattern was evident
(Figure 1A). Under general anesthesia, 2 femoral venous
punctures were performed, for a quadripolar catheter and an
ablation catheter (Navistar ThermoCool Biosense Webster,
Diamond Bar, CA) 8F irrigated curve D, in the right ventricle
(RV). Endocardial RV voltage mapping was performed with
an electroanatomic mapping system (CARTO 3; Biosense
Webster, Diamond Bar, CA), where normal electrograms
were found. Epicardial access was attempted using a sub-
xiphoid percutaneous approach and through a steerable
introducer an Agilis EPI (St Jude Medical, Minnetonka,
MN) 9F ablation catheter was advanced. RV epicardial
electroanatomic voltage mapping was then performed. Late,
fragmented, double, and triple potentials were localized in
the RV anterior region (Figure 2A). Flecainide acetate was
infused intravenously over 10 minutes (dose of 100 mg)
under ECG monitoring, and type 1 BrS was unmasked with a
3 mm elevation of ST segment in V1-V2 (Figure 1B). A new
epicardial map was performed, and a wider area of target
potentials was localized (a total area of approximately 42.56
cm2), with manifest double and triple potentials (Figure 2B).
Radiofrequency (RF) ablation with 30 W was performed,pen access article under the CC BY-NC-ND license
http://dx.doi.org/10.1016/j.hrcr.2015.09.005
KEY TEACHING POINTS
 The electrocardiogram manifestations of Brugada
syndrome are often dynamic or concealed and may
be unmasked or modulated by different
circumstances and medical drugs.
 Epicardial ablation has been done on the basis of
studies that demonstrate histologic changes, as
well as a combination of abnormal depolarization
and repolarization of right ventricle outﬂow tract.
 Flecainide infusion is useful to address the surface
covered by abnormal potentials of epicardial
origin.
 Further studies should be done to consider right
ventricular outﬂow tract epicardial ablation a
treatment option in patients with Brugada
syndrome and recurrent ventricular ﬁbrillation, but
short-term results are encouraging.
53Gonzalez-Melchor et al Epicardial Right Ventricle Mapping and Ablation During Flecainide Testing in Brugada Syndromewith progressive slowing of potentials until disappearance
(Figure 3), presenting transient ST ascendant elevation in
V1-V2 (Figure 1C). After RF ablation, ﬂecainide acetate was
infused at the same dose and endocardial RV with 2
extrastimuli decremented stimulation for ventricular tachy-
cardia (VT)/VF induction protocol was performed up to 500/
310/270 msec, in which the patient presented VF requiring
electric deﬁbrillation. RV epicardial mapping was continued
and substrate RF ablation was again performed. A new VT/
VF induction protocol was performed up to 500/310/250
msec, and VF was induced, requiring electric deﬁbrillation.
Epicardial mapping was continued, including RVOT, where
slow, fragmented, and double potentials were also observed,
and RF was delivered. A new VT/VF induction protocol
was performed with 1 and 2 extrastimuli until RV refra-ctory effective period: 500/290/200 msec, with no VT/VF
induction. Total radiofrequency duration required was 32
minutes, 30 seconds. Electrophysiological study was con-
cluded. The following day, the patient presented with acute
mild pericarditis with typical pericardial pain and ST-
segment elevation in inferior leads, so ibuprofen and
colchicine was prescribed, with good response. After 4 days
the patient was discharged with no BrS ECG pattern
(Figure 1D). Five months after the electrophysiological
study, the patient remained asymptomatic, with no VT/VF
episodes and no BrS ECG pattern persisting (Figure 1E).Conclusion
Epicardial ablation has been done on the basis of studies that
demonstrate histologic changes and abnormal activation of
RVOT.7 As in previous studies, this case supports the
hypothesis that patients with BrS have a depolarization
disorder8,9 in a “current-to-load mismatch fashion,”10 in a
relatively delimitated area of subepicardial origin5 in accord-
ance with late activation in epicardial RVOT. This could be
observed more clearly after ﬂecainide was infused and
double potentials and late depolarization were mapped in a
wider area of the RV epicardial wall. But additionally, as
described by Yan and Antzelevitch,11 we consider that it
could also be a repolarization substrate disorder.12 Accord-
ing to this hypothesis, after ﬂecainide was infused, to account
for the negative T wave in coved-type ST elevation, an
epicardial dispersion of repolarization was generated. This
dispersion creates a vulnerable window, which allows phase
2 reentry to cause a premature impulse, which triggers VT/
VF based on reentry between transmural layers. In our case,
inducibility persisted until epicardium double and late
potentials were eliminated, but also after BrS pattern and
typical repolarization (T-wave alteration) disappeared. Fur-
ther studies should be done with a longer follow-up,
especially in BrS patients with higher risk.
Figure 1 Twelve-lead electrocardiogram (ECG).A:At the beginning of electrophysiological study, BrS type 2 pattern. B:After ﬂecainide acetate intravenous
infusion. C: During radiofrequency onset. D: Final ECG at the end of electrophysiological study. E: Twelve-lead ECG 5 months after epicardial ablation.
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Figure 2 Anteroposterior view of right ventricle epicardial voltage map. Different late electrograms are shown before ablation, located predominantly in the
anterior wall and outﬂow tract. A: Before ﬂecainide acetate infusion. B: After ﬂecainide acetate infusion.
55Gonzalez-Melchor et al Epicardial Right Ventricle Mapping and Ablation During Flecainide Testing in Brugada Syndrome
Figure 3 Anteroposterior view of the right ventricle epicardial voltage map after radiofrequency (RF) ablation. Electrograms displayed before and after RF
delivery.
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